VANCOUVER, BC, CANADA (June 13, 2020) – Mota Ventures Corp. (MOTA:CSE) (1WZ:FSE) (PEMTF:OTC) (the “Company”) is pleased to announce the appointment of Roger C. Clinton, to the Advisory Board for its wholly owned subsidiary, Verrian GmbH. Clinton is active within the addiction treatment and specifically opiate addiction research sector, seeking to bring attention to the issue and enhance promising treatment options using psychedelics in conjunction with behavioral therapy through his global network.
“I’m honored to be working with the team at Mota in a patient first approach. We believe the work that we’re doing can be transformative in people’s lives as they work daily to overcome addiction,” said Roger Clinton.
On June 2nd, Mota announced the $20,000,000 acquisition of Verrian, a European pharmaceutical manufacturer of natural psilocybin extracts. Verrian is focused on psychedelic and cannabis treatments of opiate addiction. Clinton will play a vital role in advising and enhancing the patient perspective as well as helping to shape R&D efforts of our world-renowned addiction medicine experts, resulting in best of breed psychedelic derived treatments for the global marketplace.
Ryan Hoggan, Chief Executive Officer, stated “We’re honored to be working with Roger, an advocate for patient first treatment options. Roger’s work in advocacy for opiate addiction research will enhance MOTA’s research efforts and help to draw attention to our ground-breaking psychedelic research we as we jointly seek new treatments to help patients overcome addiction.”
Roger Cassidy Clinton is a true multi-hyphenate: singer-songwriter, voice-over artist, actor, author, up-close political observer (quite the understatement) and, arguably, one of the world’s biggest sports enthusiasts. He is also a living, inspiring story of recovery.
Roger, President Bill Clinton’s younger brother, is blessed with a spectacular group of friends from all walks of life, including the “who’s who” in the world of music, entertainment, sports (collegiate and professional) and, of course, politics. Working, associating and performing with people who have attained the highest levels of success in their professions has enabled Roger to forge priceless relationships that will last a lifetime. These relationships have brought him many unique, exciting experiences with more than a few once-in-a-lifetime opportunities.
Throughout it all, however, Roger has struggled with decades of alcohol and substance abuse that at one point left him clinically dead. Miraculously, medical personnel were able to revive Roger, and he improbably averted tragedy and survived. Through his personal, ongoing journey of recovery from a life complicated by addiction and trauma, Roger is grateful to have gained profound insight that he is privileged to share in order to help spread light and optimism with the world.
This press release is available for investor discussion on the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
About Mota Ventures Corp.
Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In Germany, Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.
ON BEHALF OF THE BOARD OF
MOTA VENTURES CORP.
Chief Executive Officer
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to research and development projects with the University, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally and its plans to acquire revenue-producing CBD brands and operations in Europe and North America. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.